ISDA

Deposition Date 2008-07-16

Release Date 2008-09-09

Last Version Date 2024-11-13

Entry Detail

PDB ID:

3DTW

Keywords:

TRANSFERASE

Title:

Crystal structure of the VEGFR2 kinase domain in complex with a benzisoxazole inhibitor

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Trichoplusia ni

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.90 Å

R-Value Free:

0.27

R-Value Work:

0.21

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Vascular endothelial growth factor receptor 2
Gene (Uniprot):KDR
Mutations:C817A, V916T, E990V
Chain IDs:A, B
Chain Length:314
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P35968 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

A96

Primary Citation

Discovery of amido-benzisoxazoles as potent c-Kit inhibitors.

Kunz, R.K, Rumfelt, S, Chen, N, Zhang, D, Tasker, A.S, Burli, R, Hungate, R, Yu, V, Nguyen, Y, Whittington, D.A, Meagher, K.L, Plant, M, Tudor, Y, Schrag, M, Xu, Y, Ng, G.Y, Hu, E.Show

Bioorg.Med.Chem.Lett. 18 5115 5117 (2008)

PMID: 18723346 DOI: 10.1016/j.bmcl.2008.07.111

Abstact

Deregulation of the receptor tyrosine kinase c-Kit is associated with an increasing number of human diseases, including certain cancers and mast cell diseases. Interference of c-Kit signaling with multi-kinase inhibitors has been shown clinically to successfully treat gastrointestinal stromal tumors and mastocytosis. Targeted therapy of c-Kit activity may provide therapeutic advantages against off-target effects for non-oncology applications. A new structural class of c-Kit inhibitors is described, including in vitro c-Kit potency, kinase selectivity, and the observed binding mode.

Legend

Protein

Chemical

Disease

Primary Citation of related structures